Compare URBN & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | KYMR |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 9.0B |
| IPO Year | 1995 | 2020 |
| Metric | URBN | KYMR |
|---|---|---|
| Price | $85.56 | $118.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | $92.14 | ★ $145.22 |
| AVG Volume (30 Days) | 853.0K | ★ 882.9K |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 4.06 | N/A |
| Revenue | ★ $6,165,376,000.00 | $39,211,000.00 |
| Revenue This Year | $9.52 | $153.48 |
| Revenue Next Year | $6.96 | N/A |
| P/E Ratio | $20.98 | ★ N/A |
| Revenue Growth | ★ 11.07 | N/A |
| 52 Week Low | $59.97 | $63.69 |
| 52 Week High | $93.64 | $142.92 |
| Indicator | URBN | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 45.05 |
| Support Level | $69.46 | $104.96 |
| Resistance Level | $92.11 | $119.89 |
| Average True Range (ATR) | 3.52 | 7.14 |
| MACD | -0.67 | -1.71 |
| Stochastic Oscillator | 32.04 | 5.86 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates approximately 800 stores and e-commerce platforms in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily appeals to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.